Cornerstone Therapeutics (CRTX) Inactive 10-K2007 FY Annual report

Filed: 28 Mar 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Good

New words: AAA, abandoning, abandonment, Academy, accrual, accuracy, adjunctive, advisor, Allergy, analogy, ARB, assignee, authoritative, autoimmune, backup, Biogen, bronchoconstriction, bronchospasm, Brovana, burdensome, Canaccord, CAPTISOL, cessation, Chicago, choice, classified, Commonwealth, counterclaimed, credibility, crtm, CyDex, delist, delisting, depleted, depressing, discharge, display, divestiture, doubt, doubtful, dry, effectFSP, EITFNo, Eliot, emphysema, facilitate, FAPI, FDAAA, Foley, ForceNo, France, fumarate, GAAP, GLP, greatly, Hoag, Idec, ineffective, initialForm, inititation, inRule, investor, IRS, isomer, jurisdiction, kelly, LABA, literature, lost, mail, mandate, margin, membership, mentioned, merged, metered, Microbia, morbidity, motivate, Mylan, Nevada, NHLBI, nonfinancial, Nonrefundable, Notwithstanding, ofEITF, ofRegulation, onForm, orEITF, Orencia, orFSP, pathologic, pathology, PERFOROMIST, PERFOROMISTtm, pharmacodynamic, PositionNo, Precision, prompt, pronouncement, pursing, rational, recovery, refinance, refine, Rituxan, Robertson, salmeterol, slower, smooth, Solution, Squibb, stable, sued, surrender, surrendered, Survey, taxation, thereof, titled, travel, turnover, unsatisfactory, variation, vendor, westview, wholesale, wholesaler, worthy

Removed: accident, accidental, arrive, augment, billion, build, censure, compensatory, computation, contamination, disposing, education, feature, Finnegan, forfeited, Frederick, front, handle, immunoglobin, integrin, intensive, liable, limiting, long, match, Newman, paul, paying, persistent, precautionary, productivity, promise, promissory, promoted, promulgated, ratio, reclassified, redeemable, regulate, revise, robert, rule, SAB, spill, stabilize, step, surgical, Tanox, train, trend, twelve, underserved, underwriting, unproven, utilized, Walsh, Walter, Xolair, zeiger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CRTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(b)
OF THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350

In connection with the Annual Report on Form 10-K of Critical Therapeutics, Inc. (the “Company”) for the period ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Frank E. Thomas, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

	(1)		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 28, 2008



	/s/ Frank E. Thomas
	Frank E. Thomas
	President and Chief Executive Officer (Principal Executive Officer)